Introduction and Objective: Diabetes device use in T1D is associated with improved clinical outcomes. However, many people experience device-related skin reactions. Our aim was to assess psychosocial outcomes between YYA with T1D that experience device-related skin reactions and those that do not.Methods: YYA (2-25 years) with T1D that use diabetes devices completed an in-house developed survey, and the Problem Area in Diabetes (PAID, measure of diabetes distress, higher scores indicate more distress) and diabetes-specific Pediatric Quality of Life (PedsQL, higher scores indicating better well-being) surveys. Participants were dichotomized based on experiencing skin reactions to devices. T-tests were performed on HbA1c and PAID/PedsQL outcomes.Results: Eighty-eight YYA participated (15.4±6.2 yrs, T1Ddur 6.8±5.4 yrs, HbA1c 7.0±1.0%, 59.1% Female, 88.0% NHW, 98.9% CGM users, 90.9% pump users). Those with device-related skin reactions had significantly higher PAID scores and frequent self-reported negative feelings. No other significant differences were found.Conclusion: Youth and young adults with device-related skin reactions experience diabetes distress and device-related negative feelings, which can impact device use and overall well-being. Future research should focus on mitigating skin reactions and assessing the impact on psychosocial well-being.
A.J. Karami: None. V.S. Fadhel Hernández: None. C. Sakamoto: None. K. Taylor: None. E. Fivekiller: None. C. Berget: Consultant; Insulet Corporation. Advisory Panel; Tandem Diabetes Care, Inc. Other Relationship; Tandem Diabetes Care, Inc, Insulet Corporation, embecta. S. Lange: Advisory Panel; Medtronic. E.C. Cobry: Advisory Panel; Dexcom, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases (2T32DK063687)
Source link
Leave a Reply